Фактор риска
Очень высокая волатильность
Фактор доходности
Сильно переоценена
О компании
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a novel automated device for quickly and gently separating high quality sperm from a raw semen sample for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a central lab human semen analysis from distantly located donors; and AI-Port. An ambient temperature semen transport device used for animal artificial insemination. Memphasys Limited was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. The company was incorporated in 2006 and is based in Homebush, Australia.
Оценка компании
Как с исторической, так и с прогнозной точек зрения акции значительно переоценены по сравнению с аналогичными акциями.